Evaluation Of Semaglutide Safety and Tolerability in Adults With Cocaine Use Disorder With and Without HIV

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• At least 18 years old

• Meet criteria for CUD according to the Diagnostic and Statistical Manual Version 5

• Used cocaine at least 7 out of the past 14 days

• Body Mass Index between 20 - 50 kg/m2

• English proficiency

• In people of childbearing potential, agree to use an acceptable method of birth control

Locations
United States
Washington, D.c.
Institute of Human Virology at the University of Maryland School of Medicine
RECRUITING
Washington D.c.
Maryland
Institute of Human Virology at the University of Maryland School of Medicine
RECRUITING
Baltimore
Contact Information
Primary
Onyinyechi Ogbumbadiugha-Weekes
oogbumbadiugha@ihv.umaryland.edu
443-635-4943
Backup
Sarah Kattakuzhy
skattakuzhy@ihv.umaryland.edu
443-691-4638
Time Frame
Start Date: 2025-08-07
Estimated Completion Date: 2027-03
Participants
Target number of participants: 40
Treatments
Experimental: Semaglutide
Once weekly injection of semaglutide
Placebo_comparator: Placebo
Once weekly injection of placebo
Related Therapeutic Areas
Sponsors
Collaborators: National Institutes of Health (NIH)
Leads: University of Maryland, Baltimore

This content was sourced from clinicaltrials.gov